Related Experiment Video
Updated: Aug 16, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011
PIV-3 vaccine National Institutes of Health/Aviron
1Intellivax International Inc, Ville St-Laurent, Quebec, Canada. tjones@intellivax.com
Abstract:
Wyeth-Lederle, Aviron and NIH are developing a live intranasal parainfluenza virus (PIV) type 3 vaccine (cp45 vaccine). The vaccine is in phase II/III trials with Aviron [411386], and phase I trials with Wyeth-Lederle [408940]. It consists of a temperature-sensitive PIV-3 virus attenuated with an imported L gene mutation. This addition renders the virus 5-fold more restricted for replication in the respiratory tract of chimpanzees and also more temperature-sensitive [336999].
Related Concept Videos
Vaccinations
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccine Production
Vaccines
Diphtheria
Poliomyelitis

